Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study.
about
The early result of whole pelvic radiotherapy and stereotactic body radiotherapy boost for high-risk localized prostate cancerSBRT for the Primary Treatment of Localized Prostate Cancer: The Effect of Gleason Score, Dose and Heterogeneity of Intermediate Risk on Outcome Utilizing 2.2014 NCCN Risk Stratification Guidelines.Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer.Medically inoperable peripheral lung cancer treated with stereotactic body radiation therapy.Investigation of a real-time EPID-based patient dose monitoring safety system using site-specific control limits.The Comparison of Stereotactic Body Radiation Therapy and Intensity-Modulated Radiation Therapy for Prostate Cancer by NCCN Risk Groups.Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity.Evolution of hypofractionated accelerated radiotherapy for prostate cancer - the sunnybrook experience.A review of rectal toxicity following permanent low dose-rate prostate brachytherapy and the potential value of biodegradable rectal spacers.Dose-Escalated Robotic SBRT for Stage I-II Prostate Cancer.Hypofractionated stereotactic body radiotherapy for localized prostate cancer - first Nordic clinical experience.Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: The Georgetown University Experience.Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer.Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer.Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma.Will intrafraction repair have negative consequences on extreme hypofractionation in prostate radiation therapy?Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost and whole pelvic radiotherapy for intermediate- and high-risk prostate cancer.Reducing rectal injury in men receiving prostate cancer radiation therapy: current perspectives.Propensity Score Matched Comparison of Intensity Modulated Radiation Therapy vs Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Survival Analysis from the National Cancer Database.Stereotactic body radiotherapy as treatment for organ confined low- and intermediate-risk prostate carcinoma, a 7-year study.Predicting Biochemical Disease-Free Survival after Prostate Stereotactic Body Radiotherapy: Risk-Stratification and Patterns of Failure.Predictive Factors of Late-onset Rectal Mucosal Changes After Radiotherapy of Prostate Cancer.Hypofractionated stereotactic boost in intermediate risk prostate carcinoma: Preliminary results of a multicenter phase II trial (CKNO-PRO).SPECT imaging and radionuclide therapy of glioma using 131I labeled Buthus martensii Karsch chlorotoxin.ONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I/II trial
P2860
Q34433023-4FB45CE6-47E1-42B5-8FC3-7B2F60653987Q34487782-42EDDBD0-3635-47A5-BD8A-4D7357DF756DQ35174871-01A78346-59D4-4B5F-8FF8-8FC0B8268870Q35710141-9F8B2575-2AA4-48C2-B2D3-D4B0F1A253A7Q37171399-892B315C-3DF7-4C9E-8B37-B6FF71506000Q37195789-04EA1D4E-7B14-40E7-92B6-B0A2872DD2BBQ37627132-48E2A4A8-9DC4-496A-9B5E-AF99D61CB1ECQ38276603-5B930F53-128B-4891-98EA-8739DCCD385BQ38357722-13E042F0-946A-45AC-AA29-7966A96647C0Q38437266-EB2C13E5-A3FD-4A0D-8072-85B499EA4DF8Q38780363-698E8913-9BDB-4868-B42C-FDBD6DB42FC2Q38839208-6C1EFF02-D5C0-4DA6-A1CB-7D5DC66B32DFQ39078034-B4633C0C-0553-4B8C-B687-BB6127770E7AQ39736576-304CA5A5-E46E-48EE-957C-8D58794A0EF8Q40137729-39AB7C9A-84D4-4795-9DFC-AD997D084E01Q40452434-A9E66C08-E732-4C3F-AA3F-51BD373A63A3Q40858279-BE29A41C-071E-430E-A550-1A6F93F21D64Q41276603-8867CBA2-E0F1-45AB-B0EF-235A8C512A66Q41608117-CA5D4272-4907-430C-9EC3-FE2967C5B999Q41878672-7420598B-AC95-4DA1-AA4D-A27D652A92C7Q41960300-D00C0885-304B-4D1B-A284-DC808FC09E37Q43246964-368D12B1-574C-43F9-9FEB-AE0D031F0546Q47122710-C1782858-EB9C-42DA-A1FD-62DEA2758F2CQ50659717-BAE73220-D71D-40B3-A968-3D3B909F4AF7Q58765203-3041D333-9A7D-498E-877C-6E593D3D0277
P2860
Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Stereotactic body radiotherapy ...... e carcinoma: a six year study.
@en
Stereotactic body radiotherapy ...... e carcinoma: a six year study.
@nl
type
label
Stereotactic body radiotherapy ...... e carcinoma: a six year study.
@en
Stereotactic body radiotherapy ...... e carcinoma: a six year study.
@nl
prefLabel
Stereotactic body radiotherapy ...... e carcinoma: a six year study.
@en
Stereotactic body radiotherapy ...... e carcinoma: a six year study.
@nl
P2860
P356
P1433
P1476
Stereotactic body radiotherapy ...... e carcinoma: a six year study.
@en
P2093
Josephine Kang
P2860
P2888
P356
10.1186/1748-717X-9-1
P577
2014-01-01T00:00:00Z
P5875
P6179
1004716007